Top Institutions in Ocular Oncology and Cancer Genetics
Leading institutions in ocular oncology and cancer genetics utilize advanced genetically engineered mouse models, comprehensive genomic profiling, and immunological studies to elucidate the stepwise genetic and cellular changes in uveal melanoma, enabling translational research into targeted therapies and immunotherapies.
-
#1
Memorial Sloan Kettering Cancer Center
New York, NY
MSKCC is a global leader in ocular melanoma research, with extensive programs in genetic modeling, tumor biology, and clinical trials of novel therapies, including immunotherapy approaches for metastatic uveal melanoma.
Key Differentiators
- Ocular Oncology
- Cancer Genetics
- Immunotherapy
-
#2
Wills Eye Hospital / Thomas Jefferson University
Philadelphia, PA
Wills Eye is renowned for its clinical and translational research in uveal melanoma, combining expertise in ocular oncology with molecular genetics to study tumor progression and develop novel diagnostic and therapeutic strategies.
Key Differentiators
- Ocular Oncology
- Molecular Genetics
-
#3
National Cancer Institute (NCI), NIH
Bethesda, MD
The NCI conducts cutting-edge basic and translational research on the genetics and immunology of uveal melanoma, including development of genetically engineered mouse models and studies on tumor-immune interactions.
Key Differentiators
- Cancer Genetics
- Experimental Oncology
- Immunology
-
#4
University of Texas MD Anderson Cancer Center
Houston, TX
MD Anderson integrates genomic research with clinical oncology to advance understanding of uveal melanoma genetics and immunotherapy, with active programs in experimental models and clinical trials.
Key Differentiators
- Ocular Oncology
- Cancer Genomics
- Immunotherapy
-
#5
Bascom Palmer Eye Institute, University of Miami
Miami, FL
Bascom Palmer is a leading ocular oncology center with strong research focus on molecular pathology and genetics of uveal melanoma, contributing to understanding tumor progression and metastasis.
Key Differentiators
- Ocular Oncology
- Molecular Pathology
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
